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Background:
Numerous primary care innovations emphasize patient-centered processes of care. Within the
context of these innovations, greater understanding is needed of the relationship between
improvements in clinical endpoints and patient-centered outcomes. To address this gap, we
evaluated the association between glycosylated hemoglobin (HbA1c) and diabetes-specific
quality of life among patients completing diabetes self-management programs.
Methods
We conducted a retrospective cohort study nested within a randomized comparative
effectiveness trial of diabetes self-management interventions in 75 diabetic patients. Multiple
linear regression models were developed to examine the relationship between change in
HbA1c from baseline to one-year follow-up and Diabetes-39 (a diabetes-specific quality of
life measure) at one year.
Results
HbA1c levels improved for the overall cohort from baseline to one-year follow-up (t
(74) = 3.09, p = .0029). One-year follow up HbA1c was correlated with worse overall quality
of life (r = 0.33, p = 0.004). Improvements in HbA1c from baseline to one-year follow-up
were associated with greater D-39 diabetes control (β = 0.23, p = .04) and D-39 sexual
functioning (β = 0.25, p = .03) quality of life subscales.
Conclusions
Improvements in HbA1c among participants completing a diabetes self-management
program were associated with better diabetes-specific quality of life. Innovations in primary
care that engage patients in self-management and improve clinical biomarkers, such as
HbA1c, may also be associated with better quality of life, a key outcome from the patient
perspective.
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BACKGROUND
Literature Review
Diabetes Mellitus is among the most prevalent chronic illnesses in the United States,
affecting nearly 24 million Americans [1]. In response to the Institute of Medicine’s calls for
patient-centeredness [2], innovations in diabetes care have increasingly made patients’
perspectives central to the process and outcomes of care. These advances, which include the
Chronic Care Model [3], the Patient-Centered Medical Home [4], and various patientengagement interventions [5,6], all focus on patient-centeredness in the process of care.
However, there is a need to move beyond the process of care and develop patient-centered
outcomes to assess the impact of these innovations from the patient perspective.
As with many chronic diseases, diabetes patients are less concerned with clinical
biomarkers [7] such as hemoglobin A1c, blood pressure, or lipid levels, and are more
concerned with physical and social function, emotional and mental health, and the burden of
illness and treatments on daily life [8]. Quality of life measures, which include many of these
domains [9] are thus more meaningful and relevant outcomes from the patient perspective.
The development of quality of life measures that are associated with future clinical outcomes
would enhance shared decision making by framing treatment options in a context that is
pertinent to patients [10].
In diabetes care, general health status measures such as the SF-36 and the EQ-5D are
commonly used to assess patients’ quality of life [11-18]. Although these measures are useful
in comparing patient health status across different illnesses, they often cannot capture
distinctive aspects of specific diseases [19]. Quality of life measures that are disease-specific
1

and associated with clinical outcomes have been developed in other chronic illnesses. For
instance, a number of disease-specific quality of life measures in cardiovascular disease
[10,20-22] and cancer [23-28] are predictive of subsequent morbidity and mortality. Diabetes
places significant self-management responsibility on patients, and thus warrants the
development and validation of clinically relevant and patient-centered quality of life
measures. Recent structured reviews [9,29,30] have identified several disease-specific quality
of life measures for diabetes. Unfortunately, attempts to understand the association between
these quality of life measures and common clinical biomarkers, such as HbA1c, have been
inadequate [9,29,30].

Public Health Significance
Although diabetes represents one of the most prevalent and costliest chronic diseases
in America, diabetes management overwhelmingly focuses on esoteric measurements of
long-term glucose control, such as HbA1c. However, this measure is inherently irrelevant
and even somewhat arbitrary for patients, as the numerical value itself has little meaning to
non-clinicians. Thus, there is a need to correlate clinical values such as HbA1c to meaningful
real-world outcomes that are relevant from the patient perspective. This includes correlating
HbA1c to patient-reported quality of life, which is arguably the most relevant outcome from
the patient perspective. The results of this study would allow clinicians to frame changes in
HbA1c in the context of patient-reported outcomes, in turn allowing patients to become more
engaged in their own self-management and participate more meaningfully in shared decision
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making. This has potential to improve the overall quality of diabetes care delivered in our
healthcare system.

Hypothesis, Research Question, Specific Aims or Objectives
We aim to conduct a retrospective cohort study nested within a randomized comparative
effectiveness trial of diabetes self-management interventions in order to explore the
following specific aims:

1) To investigate the association between HbA1c and diabetes-specific quality of life, as
measured by the Diabetes-39 health-related quality of life measure.
2) To evaluate the relationship between diabetes-specific quality of life and HbA1c both
before and after participants completed diabetes self-management programs.
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METHODS
Study design
This study was a retrospective cohort study nested within a pilot randomized
comparative effectiveness trial conducted among diabetic patients at the Michael E. Debakey
Veterans Affairs Medical Center (MEDVAMC). The trial randomized eligible participants to
the Empowering Patients in Chronic Care (EPIC) goal setting intervention or to a diabetes
self-management and nutrition education intervention. The primary study was conducted
among 50–90 year old type II diabetes mellitus patients with primary care providers (PCPs)
within the VA healthcare system. This secondary analysis included all participants from the
original study who had HbA1c ≥ 7.0% at baseline, completed either of the two selfmanagement programs, had HbA1c measurements in the VA clinic database at one-year
follow-up, and returned completed one-year follow-up questionnaires.

Diabetes self-management programs
All participants in our retrospective cohort completed one of two diabetes selfmanagement programs. Both programs were conducted in group settings, included diabetes
self-management education, and focused on educating participants about key clinical
indicators in diabetes and the importance of integrating patient self-management into daily
life. Each program included a ten minute one-on-one session with either a clinician or a
diabetes educator to go over participants’ individual HbA1c, blood pressure, and cholesterol
levels. The aim of the 1-on-1 personal sessions in both programs was to help participants
individualize the diabetes self-management information. The Empowering Patients in
4

Chronic Care (EPIC) intervention included didactic and problem-based discussions on goalsetting and action planning as well as patient-physician communication. The traditional
diabetes education intervention included information on diabetes medications, associated
health problems, meal preparation, and portion size and control. The complete methodology
of the randomized comparative effectiveness study has been published elsewhere [6].

Data collection
All data used in this study were collected during the EPIC pilot randomized
comparative effectiveness trial after approval from the Baylor College of Medicine
Institutional Review Board and the MEDVAMC research and development committee. No
additional data were collected for this retrospective cohort study.
Clinical information, including hemoglobin A1c and body mass index, was collected and then
extracted from participants’ medical record in the MEDVAMC clinic database. Participants
also completed questionnaires with a variety of self-reported data at baseline and one-year.
Diabetes-related burden of illness was assessed at baseline as a proxy for diabetes-specific
quality of life using a measure adapted from the Diabetes Care Profile Section VII [19]. This
13-item measure asks participants about aspects of their daily lives that diabetes interferes
with, the burden of diabetes on personal finances, and how difficult life with diabetes is.
Responses are along a 5-point Likert scale, with higher scores indicating a greater diabetesrelated burden of illness. Individual diabetes burden of illness scores are calculated as the
mean of all items, and thus range from 1–5. A co-morbidity score was determined using a
measure derived from the Deyo modification of the Charlson Comorbidity Index [31].
5

Diabetes-39: A diabetes specific quality of life questionnaire
Diabetes-related quality of life was assessed at one-year using the Diabetes-39 [32].
This 39-item self-administered instrument measures patients’ self-assessed quality of life,
and includes 5 domains: diabetes control, anxiety and worry, social burden, sexual
functioning, and energy and mobility. Respondents were asked “how much was the quality of
your life affected by” a wide range of aspects of diabetes illness and its treatments in the past
month. Possible responses are along a 7-point scale, and range from “Not affected at all” (=1)
to “Extremely affected” (=7). Domain scores were calculated by summing the responses and
then applying a linear transformation to a 0–100 scale. An overall quality of life score was
calculated using all 39 items in the questionnaire. Scores closer to 0 indicate a better quality
of life. The instrument has undergone tests for internal consistency (Cronbach’s
alpha = 0.81–0.93; item-total correlation = 0.50–0.84), construct validity using the SF-36
Health Status Questionnaire, and a factor analysis, which found that five factors accounted
for 90% of variance [33].

Statistical analysis
We used descriptive statistics to characterize the cohort at baseline. Normality of
continuous variables was assessed with Shapiro-Wilks test. Continuous variables were
described using means, standard deviations, medians, and interquartile ranges, whereas
categorical variables were described using counts and percents. Those who returned the
follow-up survey at one year were compared to those who did not return the survey on
6

demographic and clinical characteristics using Fishers Exact Test and the Wilcoxon Mann–
Whitney test. The Wilcoxon signed rank sum test was used to compare change in
HbA1c from baseline to one-year follow-up and the Spearman Brown correlation (rsb) was
calculated to assess the relationship between one-year HbA1c and overall quality of life.
Multiple linear regression models were created to assess the relationships between change in
HbA1c from baseline to one-year and quality of life at one-year. Change in HbA1c was
calculated by subtracting baseline scores from 1 year scores. Therefore, higher scores
indicated less improvement in HbA1c. Six regression models were conducted to separately
predict the overall quality of life score and each of the five quality of life subscales.
Treatment group (where diabetes education = 0 and EPIC intervention = 1) and baseline
burden of illness were included as covariates in all six models. Because baseline Diabetes-39
quality of life scores were not available, baseline burden of illness served as a proxy for
baseline quality of life. All analyses were performed using SAS software, version 9.2 (SAS
Institute Inc, Cary, NC).
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Background
Diabetes Mellitus is among the most prevalent chronic illnesses in the United States,
affecting nearly 24 million Americans [1]. In response to the Institute of Medicine’s calls for
patient-centeredness [2], innovations in diabetes care have increasingly made patients’
perspectives central to the process and outcomes of care. These advances, which include the
Chronic Care Model [3], the Patient-Centered Medical Home [4], and various patientengagement interventions [5,6], all focus on patient-centeredness in the process of care.
However, there is a need to move beyond the process of care and develop patient-centered
outcomes to assess the impact of these innovations from the patient perspective.
As with many chronic diseases, diabetes patients are less concerned with clinical
biomarkers [7] such as hemoglobin A1c, blood pressure, or lipid levels, and are more
concerned with physical and social function, emotional and mental health, and the burden of
illness and treatments on daily life [8]. Quality of life measures, which include many of these
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domains [9] are thus more meaningful and relevant outcomes from the patient perspective.
The development of quality of life measures that are associated with future clinical outcomes
would enhance shared decision making by framing treatment options in a context that is
pertinent to patients [10].
In diabetes care, general health status measures such as the SF-36 and the EQ-5D are
commonly used to assess patients’ quality of life [11-18]. Although these measures are useful
in comparing patient health status across different illnesses, they often cannot capture
distinctive aspects of specific diseases [19]. Quality of life measures that are disease-specific
and associated with clinical outcomes have been developed in other chronic illnesses. For
instance, a number of disease-specific quality of life measures in cardiovascular disease
[10,20-22] and cancer [23-28] are predictive of subsequent morbidity and mortality. Diabetes
places significant self-management responsibility on patients, and thus warrants the
development and validation of clinically relevant and patient-centered quality of life
measures. Recent structured reviews [9,29,30] have identified several disease-specific quality
of life measures for diabetes. Unfortunately, attempts to understand the association between
these quality of life measures and common clinical biomarkers, such as HbA1c, have been
inadequate [9,29,30].
We conducted a retrospective cohort study nested within a randomized comparative
effectiveness trial of diabetes self-management interventions to investigate the association of
HbA1c and diabetes-specific quality of life. We evaluated the relationship between diabetesspecific quality of life and HbA1c both before and after participants completed diabetes selfmanagement programs.
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Methods
This study was a retrospective cohort study nested within a pilot randomized
comparative effectiveness trial conducted among diabetic patients at the Michael E. Debakey
Veterans Affairs Medical Center (MEDVAMC). The trial randomized eligible participants to
the Empowering Patients in Chronic Care (EPIC) goal setting intervention or to a diabetes
self-management and nutrition education intervention. The primary study was conducted
among 50–90 year old type II diabetes mellitus patients with primary care providers (PCPs)
within the VA healthcare system. This secondary analysis included all participants from the
original study who had HbA1c ≥ 7.0% at baseline, completed either of the two selfmanagement programs, had HbA1c measurements in the VA clinic database at one-year
follow-up, and returned completed one-year follow-up questionnaires.
All participants in our retrospective cohort completed one of two diabetes selfmanagement programs. Both programs were conducted in group settings, included diabetes
self-management education, and focused on educating participants about key clinical
indicators in diabetes and the importance of integrating patient self-management into daily
life. Each program included a ten minute one-on-one session with either a clinician or a
diabetes educator to go over participants’ individual HbA1c, blood pressure, and cholesterol
levels. The aim of the 1-on-1 personal sessions in both programs was to help participants
individualize the diabetes self-management information. The Empowering Patients in
Chronic Care (EPIC) intervention included didactic and problem-based discussions on goalsetting and action planning as well as patient-physician communication. The traditional
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diabetes education intervention included information on diabetes medications, associated
health problems, meal preparation, and portion size and control. The complete methodology
of the randomized comparative effectiveness study has been published elsewhere [6].
All data used in this study were collected during the EPIC pilot randomized
comparative effectiveness trial after approval from the Baylor College of Medicine
Institutional Review Board and the MEDVAMC research and development committee. No
additional data were collected for this retrospective cohort study.
Clinical information, including hemoglobin A1c and body mass index, was collected
and then extracted from participants’ medical record in the MEDVAMC clinic database.
Participants also completed questionnaires with a variety of self-reported data at baseline and
one-year. Diabetes-related burden of illness was assessed at baseline as a proxy for diabetesspecific quality of life using a measure adapted from the Diabetes Care Profile Section VII
[19]. This 13-item measure asks participants about aspects of their daily lives that diabetes
interferes with, the burden of diabetes on personal finances, and how difficult life with
diabetes is. Responses are along a 5-point Likert scale, with higher scores indicating a greater
diabetes-related burden of illness. Individual diabetes burden of illness scores are calculated
as the mean of all items, and thus range from 1–5. A co-morbidity score was determined
using a measure derived from the Deyo modification of the Charlson Comorbidity Index
[31].
Diabetes-39: A diabetes specific quality of life questionnaire
Diabetes-related quality of life was assessed at one-year using the Diabetes-39 [32].
This 39-item self-administered instrument measures patients’ self-assessed quality of life,
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and includes 5 domains: diabetes control, anxiety and worry, social burden, sexual
functioning, and energy and mobility. Respondents were asked “how much was the quality of
your life affected by” a wide range of aspects of diabetes illness and its treatments in the past
month. Possible responses are along a 7-point scale, and range from “Not affected at all” (=1)
to “Extremely affected” (=7). Domain scores were calculated by summing the responses and
then applying a linear transformation to a 0–100 scale. An overall quality of life score was
calculated using all 39 items in the questionnaire. Scores closer to 0 indicate a better quality
of life. The instrument has undergone tests for internal consistency (Cronbach’s
alpha = 0.81–0.93; item-total correlation = 0.50–0.84), construct validity using the SF-36
Health Status Questionnaire, and a factor analysis, which found that five factors accounted
for 90% of variance [33].
We used descriptive statistics to characterize the cohort at baseline. Normality of
continuous variables was assessed with Shapiro-Wilks test. Continuous variables were
described using means, standard deviations, medians, and interquartile ranges, whereas
categorical variables were described using counts and percents. Those who returned the
follow-up survey at one year were compared to those who did not return the survey on
demographic and clinical characteristics using Fishers Exact Test and the Wilcoxon Mann–
Whitney test. The Wilcoxon signed rank sum test was used to compare change in HbA1c
from baseline to one-year follow-up and the Spearman Brown correlation (rsb) was
calculated to assess the relationship between one-year HbA1c and overall quality of life.
Multiple linear regression models were created to assess the relationships between
change in HbA1c from baseline to one-year and quality of life at one-year. Change in HbA1c
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was calculated by subtracting baseline scores from 1 year scores. Therefore, higher scores
indicated less improvement in HbA1c. Six regression models were conducted to separately
predict the overall quality of life score and each of the five quality of life subscales.
Treatment group (where diabetes education = 0 and EPIC intervention = 1) and baseline
burden of illness were included as covariates in all six models. Because baseline Diabetes-39
quality of life scores were not available, baseline burden of illness served as a proxy for
baseline quality of life. All analyses were performed using SAS software, version 9.2 (SAS
Institute Inc, Cary, NC).

Study Results
We identified a cohort of participants completing one of two diabetes selfmanagement programs as part of a randomized comparative effectiveness trial. The current
study draws from the 94 participants who were consented and enrolled as part of the original
comparative effectiveness trial. We excluded 14 participants from our cohort who did not
return one-year follow-up questionnaires. Four additional participants were excluded for
having baseline HbA1c below 7.0%, and one participant was excluded due to an incomplete
D-39 questionnaire. A total of 75 participants were included in the analytical cohort for this
study.
Table 1 describes the baseline characteristics of the study cohort. Those with baseline
HbA1c of at least 7.0% who did not return the follow-up questionnaire (n = 11) were not
significantly different from study includes (n = 75) on any of the demographic or clinical
characteristics reported in Table 1 (all ps > .05, data for non-respondents not reported). The
13

cohort was predominantly older men of diverse education and racial/ethnic backgrounds,
with multiple morbidities and elevated BMI and HbA1c levels at baseline.
Significant improvements in HbA1c levels were observed for the cohort from
baseline to one-year follow-up, S = −574, p = .001. At follow-up, mean scores for overall
quality of life and diabetes control, anxiety and worry, and energy and mobility subscale
scores were similar to each other. Social burden subscale scores were better than overall
quality of life scores, while sexual functioning subscale scores were worse than overall
quality of life scores.
Higher one-year HbA1c scores were associated with worse overall quality of life (rsb = 0.37,
p = 0.001). We conducted a series of six multiple linear regression models to assess the
relationship between change in HbA1c from baseline to one-year and Diabetes-39 quality of
life (overall and for each subscale) at one-year. Results are presented in Table 2, with all
models adjusting for burden of illness at baseline and treatment group. Irrespective of
intervention group assignment and baseline burden of illness, improved HbA1c levels from
baseline to one-year follow-up were significantly associated with greater quality of life on
the diabetes control (β = 0.23, p = .04) and sexual function subscales (β = 0.25, p = .03).
Change in HbA1c from baseline to one-year was not associated with greater overall quality
of life or the anxiety/worry, social burden, or energy and mobility subscales. The R2 values
for the diabetes control, sexual function, and energy and mobility subscale models were
significant, indicating that these models explain a significant amount of the variability in
their respective diabetes-specific quality of life subscales.
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Discussion
We constructed a retrospective cohort of participants drawn from a randomized
comparative effectiveness study to evaluate the relationship between change in HbA1c and
Diabetes-39 quality of life. HbA1c at one-year follow-up was significantly associated with
overall quality of life on the Diabetes-39. Our multiple linear regression models suggest that
improvements in HbA1c among patients completing diabetes self-management interventions
are significantly associated with increased quality of life on the diabetes control and sexual
functioning subscales of the Diabetes-39. No association was established between changes in
HbA1c and the anxiety and worry, social burden, and energy and mobility subscales.
Baseline burden of illness, a proxy for baseline quality of life, predicted overall quality of life
as well as all subscales of the Diabetes-39, as expected.
This study firmly establishes the relationship between improved HbA1c, a critical
clinical biomarker in diabetes, and the Diabetes-39, a patient-centered diabetes-specific
quality of life measure among patients completing a self-management education program.
Several previous studies have attempted to explore the relationship between clinical
indicators, such as HbA1c, and a variety of diabetes-specific quality of life measures [31,3440]. Unfortunately, these associations have been weak [41] or nonexistent [42], present for
only very few of a scale’s domains [36], or are specific to type 1 diabetes only [34,35].
Further, prior studies report on measures that have poor evidence for validity and reliability
[32,35,36,41], focus on singular aspects of quality of life (e.g., distress [37,38,41]), ignore
key components of quality of life such as physical and social functioning [9], or include
several items that are not diabetes-specific [9]. Additionally, several reviews of diabetes15

specific quality of life measures [9,29,30] have recognized the lack of empirical evidence on
the responsiveness of these scales to changes in health status.
This analysis of HbA1c and diabetes-specific quality of life addresses many of the
limitations of prior studies. The Diabetes-39 diabetes-specific quality of life measure has
been recommended for use in research and clinical settings by all of the aforementioned
reviews of diabetes-specific quality of life measures [9,29,30]. The instrument has good
evidence for validity and reliability, includes several domains that cover many aspects of
quality of life, and is applicable to a wide population of patients [9,29,30,33]. The Diabetes39 is one of few diabetes-specific quality of life measures that have been shown to be
responsive to changes in health status [39]. Further, this instrument does not impose a
definition of quality of life upon respondents, but instead allows patients to frame responses
in the context of their own personal conceptualization of quality of life. Also, patients were
directly involved in the selection of items for the questionnaire [33]. These attributes make
the instrument highly patient-centered, one of the most critical components to any patientassessed quality of life measure. Thus, our study focuses on a diabetes-specific quality of life
measure that is a prime candidate for analysis.
Our statistical methods also address several prior studies’ shortcomings. While most previous
attempts to examine the relationship between HbA1c and quality of life used simple linear
correlations [34,41,42], our analyses included predictive linear regression models. This
allows for a more robust analysis and provides a quantification of the impact of HbA1c on
quality of life. To our knowledge, two prior studies have employed linear regression models
to assess this relationship [37,38]. However, one study [38] grouped continuous HbA1c data
16

into two groups. This reduces a model’s ability to quantify the effect of changes in HbA1c on
quality of life, and diminishes the overall robustness of the model. A second study [37]
modeled HbA1c as the primary dependent variable. This is not in line with the Institute of
Medicine’s vision [2] in which patient-centered measures, such as quality of life, are the
ultimate outcomes of care. Our analysis included a regression of continuous HbA1c data with
quality of life as the primary outcome.
Few prior studies have examined the relationship between clinical indicators and
diabetes-specific quality of life measures among participants who all completed diabetes selfmanagement programs. These programs were deeply embedded in primary care. One
program was led by a primary care physician, while the other was led by nurse educators and
registered dieticians. The latter model represents the type of delivery system redesign that is
characteristic to many primary care innovations [3,4]. Our examination of the relationship
between clinical indicators and quality of life outcomes in the context of patient-centered
diabetes self-management programs demonstrates that HbA1c improvements among
participants in these programs are associated with better quality of life. Previous studies have
included diabetes-specific quality of life among outcome measures [40,43]. These studies
approach both quality of life and HbA1c as distinct outcomes, and do not explore the
association between the two variables. Unlike prior studies, our study examines the
relationship between changes in HbA1c and diabetes-specific quality of life. In the postACCORD era, there has been reduced emphasis on intensive HbA1c control [44]. However,
the current study suggests that improved HbA1c resulting from diabetes self-management
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interventions is associated with better diabetes-specific quality of life. Thus, HbA1c control
is relevant to patient-centered outcomes and should remain a valuable goal in diabetes care.
There were limitations to our study. A sample size of 75 limited the range of analytic
strategies that could be employed. The sample size may also have affected the power of our
analyses, which may account for the weak association between changes in HbA1c and some
of the Diabetes-39 subscales. The generalizability of our study may also be limited. Our
sample is reflective of the United States Veterans Administration patient population,
consisting largely of older patients who are predominantly male, of older age, and have
significant co-morbidities. Further, all of the participants in our cohort participated in at least
one diabetes self-management program. Thus, we were unable to assess the impact of
participation in these programs on quality of life as compared with patients who did not
participate in any self-management programs. Additionally, the lack of Diabetes-39 data at
baseline precluded an examination of the responsiveness of this diabetes-specific quality of
life measure over time. However, our analysis does include HbA1c data from multiple time
points and includes a measure of burden of illness at baseline. Many previous studies used
cross-sectional data from one time point [34,37,41,42]. Our analyses included HbA1c data
from both before and after participation in diabetes self-management programs.
Future studies should be certain to collect quality of life data both before and after
diabetes self-management programs so that the responsiveness of quality of life measures can
be assessed. Subsequent studies should also include larger, more diverse samples to ensure
adequate power and generalizability. The inclusion of a control group that does not receive
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any programs beyond routine care may also allow for future examinations of the impact of
diabetes-self management programs on quality of life.

Conclusion
Improved HbA1c levels among participants in diabetes self-management programs
are associated with higher diabetes-specific quality of life scores. These findings suggest that
innovations in primary care focused on patient engagement may not only improve traditional
clinical outcomes, but are associated with better patient-centered quality of life outcomes.

Table 1: Descriptive Statistics for n=75 patients.
Mean (SD)

Median (IQR)

Age in years

64.03 (7.56)

63.00 (9.00)

Baseline Burden of illnessb

2.61 (0.81)

2.77 (1.30)

Baseline Body mass index (n = 66)

33.38 (5.86)

32.16 (5.59)

Deyo comorbidity index (n = 71)

3.66 (2.55)

3.00 (3.00)

Baseline

8.82 (1.20)

8.60 (1.40)

1-year

8.28 (1.40)

7.90 (1.40)

41.36 (23.32)

40.33 (35.05)

Hemoglobin A1c %

1-year Diabetes QOL
Overall
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Mean (SD)

Median (IQR)

Diabetes control

42.24 (26.90)

43.06 (48.62)

Anxiety/worry

37.94 (30.25)

37.50 (58.34)

Social burden (n = 74)

23.96 (26.32)

13.33 (40.00)

Sexual functioning (n = 74)

60.65 (34.34)

66.67 (50.00)

Energy and mobility

43.10 (25.83)

43.33 (41.11)

Frequency (Percent)
Male

73 (97.33)

Race/Ethnicity (n = 74)
White

38 (51.35)

Black

21 (28.38)

Hispanic

12 (16.22)

Other

3 (4.05)

Education Levela
≤ High School

21 (28.00)

Some College/Trade School

54 (72.00)

VA co-pay
Required

25 (33.33)

Waived

50 (66.67)
20

a

Highest completed education level.
Adapted from a subscale of the Diabetes Care Profile (Fitzgerald 1996).
SD = standard deviation; IQR = inter-quartile range.
b

Table 2. Multiple Regression Models Predicting Overall QOL and QOL Subscales at One
Year (N = 75)
Overall
Diabetes
Anxiety/
Social
Sexual
Energy
QOLa
Control
Worry
Burden Function
and
Mobility
β

p

β

p

β

p

β

p

β

p

β

p

.17

.13

.23

.04

.10

.42

.10

.40

.25

.03

.05

.64

Treatment
Condition c
(0 = DM
education;
1 = EPIC)

.05

.68

-.04

.74

.04

.71

.05

.70

-.03

.81

-.07

.54

Baseline
Burden
Inventory

.36

.002

.37

.001

.27

.019

.24

.04

.24

.04

.35

.003

Change in
Hemoglobin
A1c
(baseline –
1 year) b
Covariates

R2

.18**

.21**

.10

a

.08

.14*

.14*

Lower scores indicate better quality of life.
Lower scores indicate more improvement.
c
Treatment Condition = randomization to either Diabetes Mellitus (DM) Education Group
Intervention or Empowering Patients in Chronic care (EPIC) Intervention.
* p < .05, ** p < .01.
b
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CONCLUSION
Improved HbA1c levels among participants in diabetes self-management programs
are associated with higher diabetes-specific quality of life scores. These findings suggest that
innovations in primary care focused on patient engagement may not only improve traditional
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This study was limited by its use of only a single diabetes-specific quality of life
measure. Thus, while this study did validate the use of the Diabetes-39 as a metric that is
correlated to changes in objective HbA1c values, future studies should attempt to perform
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